1. Home
  2. LEE vs ADAG Comparison

LEE vs ADAG Comparison

Compare LEE & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lee Enterprises Incorporated

LEE

Lee Enterprises Incorporated

HOLD

Current Price

$7.69

Market Cap

175.8M

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.65

Market Cap

254.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEE
ADAG
Founded
1890
2011
Country
United States
China
Employees
N/A
N/A
Industry
Newspapers/Magazines
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
175.8M
254.4M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
LEE
ADAG
Price
$7.69
$3.65
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.25
AVG Volume (30 Days)
33.6K
168.9K
Earning Date
05-07-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$543,955,000.00
N/A
Revenue This Year
$5.48
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.34
$1.44
52 Week High
$9.97
$4.75

Technical Indicators

Market Signals
Indicator
LEE
ADAG
Relative Strength Index (RSI) 39.83 49.13
Support Level $3.77 $3.40
Resistance Level $9.26 $3.99
Average True Range (ATR) 0.42 0.29
MACD -0.05 -0.00
Stochastic Oscillator 33.08 70.90

Price Performance

Historical Comparison
LEE
ADAG

About LEE Lee Enterprises Incorporated

Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: